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Chapter 1 
Introduction and General Overview
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Introduction and General Overview 
Ischemic heart disease remains a major cause of mortality and morbidity in Europe, the United 
States and Japan. It has been proposed that coronary atherosclerosis is the consequence of the 
vascular response to injurious effects of exposure to the classical cardiovascular risk factors 
including smoking, diabetes, hypertension and hyperlipidemia. However, the relationship 
between such coronary risk factors and atherosclerotic coronary plaque burden has not yet been 
fully elucidated. The epidemic of cardiovascular disease demands further efforts to elucidate the 
mechanisms of atherosclerosis and further research to develop and guide treatments. Since 
Andreas R. GrĦntzig performed the first percutaneous transluminal coronary angioplasty on 
September 6th 977, coronary intervention has become accepted as an effective therapy for 
patients with coronary artery disease all over the world.  The initial success achieved with 
percutaneous coronary intervention continues to be limited by restenosis. Intracoronary 
ultrasound (IVUS) studies reveal that late vessel remodeling and plaque growth plays an 
important role in the restenosis process.  Coronary stenting, by supporting the vessel wall, 
limits early and late vessel remodeling and subsequently decreases restenosis.  More recently 
short- to medium-term restenosis appears to have been further ameliorated by the advent of 
drug-eluting stent (DES) technologies. However, several limitations still restrict the widespread 
application of this technique including concerns about subacute or late stent thrombosis, the 
limited success rates of PCI for complex lesion morphology (e.g. chronic total occlusion (CTO)) 
and interventional cost.  The ultimate goal of interventional cardiology is to disclose the 
mechanism of progression and regression of coronary atherosclerosis, and to provide less 
invasive and more effective treatments for the patients suffering from ischemic heart disease.  
Each interventional device should be carefully sized and deployed using reliable techniques 
such as intracoronary ultrasound (IVUS) and quantitative coronary angiography (QCA). 
Part I of this thesis (Chapters 2 to 4) addresses the reliability of three methodologies 
including quantitative coronary angiography (QCA), intracoronary ultrasound (IVUS) and 
coronary angioscopy.  In Chapter 2, we validate intracoronary ultrasound (IVUS) 
measurements and quantitative coronary angiography (QCA) by using geometric and 
densitometric techniques.  In Chapter 3, we report the results of experimental and clinical 
QCA comparison between cinefilm and digital video recording with and without edge 
enhancement.   
Pathological studies support the common beliefs that lipid-rich coronary plaques with 
13
a thin, fibrous cap are prone to rupture, and that the rupture and superimposed thrombosis are the
primary mechanisms causing acute coronary syndromes such as unstable angina. In Chapter 4,
to examine the mechanism of the plaque rupture, we compared unstable and stable lesions using 
three imaging modalities: IVUS, QCA and coronary angioscopy.  
Having validated our primary methodological techniques, Part II of this thesis 
(Chapters 5 to 8) proceeds with the sequential evaluation of progression and regression of 
coronary atherosclerosis in relation to abnormal vasomotor tone and smoking status.  The 
primary role of coronary spasm in vasospastic angina and certain categories of myocardial 
infarction are established. While it has been known for decades that coronary spasm frequently 
occurs at sites of significant atherosclerosis, it has not yet been determined whether vasospasm 
may play a role in the progression or regression of atherosclerosis.  In Chapter 5, we examine 
the impact of vasospastic activity on the progression and regression of coronary atherosclerosis 
by QCA.  In Chapter 6, we examine the influence of long-term vasospastic activity on clinical 
presentations. In Chapter 7, we compared basal coronary tone and vasospastic activity by 
measuring changes in the mean luminal diameter of each entire spastic segment, segments 
adjacent to the spastic segment, and segments in non-spastic vessels at baseline, after 
administration of ergonovine and after administration of isosorbide dinitrate using QCA. 
Although cigarette smoking is a strong risk factor for coronary artery disease, the 
exact effects of the smoking habit on coronary plaque burden and restenosis after PCI remain 
uncertain. In Chapter 8, using the QCA and IVUS techniques and knowledge obtained in the 
Thoraxcenter Erasmus University Rotterdam, we examined the relationship between smoking 
status and plaque burden, vascular remodeling and restenosis in 039 patients undergoing PCI.  
We performed stenting or balloon angioplasty with either IVUS guidance (450 patients) or 
angiography-guidance alone (589 patients) in both European and Japanese patients.   
Using our primarily validated methodologies and techniques, in Part III of this thesis 
(Chapter 9 to 13) we examine the short- and long-term efficacy of coronary stent implantation 
as well as cutting balloon angioplasty.  In Chapter 9, we hypothesized that oversized Wallstent 
implantation with a policy of "restitutio ad integrum" (resetting the vessel size into undiseased 
condition) would produce enforced mechanical remodelling of the coronary vessel with 
subsequent reduction in restenosis rates.  To test this hypothesis we performed Wallstent 
implantations in native coronary arteries with acute or threatened closure post balloon 
angioplasty and assessed long-term outcome by the serial QCA. Since restenosis after 
successful dilatation of chronic total occlusions (CTO) is significantly higher than after 
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successful dilatation of non-occluded stenoses, in Chapter 10 we examined this strategy of 
oversized Wallstent deployment after successful laser or balloon angioplasty.  QCA was 
performed pre-intervention, post-balloon angioplasty, post-high pressure balloon angioplasty 
after oversized Wallstent deployment, and at 6 months follow-up.  In Chapter 11, we report 
our initial experience with the AVE stent primarily in the domain of multiple stenting of long 
and complex coronary dissections.  In Chapter 12, the problem of restenosis assessment 
within the radiopaque tantalum Cordis stent is assessed by IVUS and QCA using both geometric 
and densitometric techniques in both an experimental restenosis model and in the clinical 
follow-up of patients.  
Applying the QCA and IVUS techniques and knowledge obtained in the Thoraxcenter 
Erasmus University Rotterdam in Chapter 13 we report the results of a Japanese multicenter 
study to determine the long-term efficacy of cutting balloon angioplasty (CBA) prior to stenting 
strategy.  We investigated whether IVUS-guided Cutting Balloon Angioplasty (CBA) before 
stenting could achieve restenosis rates comparable to those achieved with drug-eluting stents 
(DES). We randomized 52 patients to CBA before stenting (260 pts) or plain old balloon 
angioplasty (POBA) before stenting. IVUS-guided procedures were performed in 279 (54%) 
patients and angiography guidance was used in the remainder.  
In the final part of this thesis (Chapter 14) we examine the role and usefulness of 
IVUS and QCA as techniques for investigating the mechanisms of coronary atherosclerosis and 
the potential scope for their use in evaluating the short and long-term success of coronary 
interventions.
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ABSTRACT:
Background: Although smoking is an established risk factor for coronary atherosclerosis, its 
influence on vascular remodeling and plaque burden is uncertain. Similarly, the impact of 
smoking status on restenosis after percutaneous coronary intervention (PCI) is unclear. 
Methods and Results: We examined the relationship between smoking status and plaque burden, 
vascular remodeling and restenosis in 039 patients undergoing PCI. Intravascular ultrasound 
examination was performed in 450 patients to determine vessel area (VA), lumen area (LA) and 
plaque area. Remodeling index was defined as the ratio between lesion and average reference 
VA.  Restenosis was defined as >50% diameter stenosis at follow-up. Of the 039 patients, 248 
were current smokers, 468 ex-smokers and 323 non-smokers. Current smokers were more likely 
to be younger than ex-smokers or non-smokers (56.8r9.9 v 60.3r9.8 v 64.5r9.5 years, 
P=0.00), and to suffer from unstable angina (25.0% v 3.5% v 3.6%, P=0.00). Current 
smokers had a significantly greater plaque burden in the lesion (3.6r4.6mm2 v .r4.mm2
v 0.6r3.8mm2, P=0.00) as well as in the reference segments (7.7±3.7 mm2 v 6.3±2.5mm2 v
6.0±2.7mm2, P=0.00) and were more likely to have a positive remodeling index (.04r0.23 v
0.96r0.20 v 0.94r0.7, P=0.00). Restenosis rates were similar between the three groups 
(25.4% v 24.6% v 24.3%, P=0.955).
Conclusions: Although restenosis was not affected by smoking, current smoking appears to 
result in an earlier and unstable presentation of coronary disease, reinforcing the importance of 
smoking cessation. 
INTRODUCTION:
Current models describe atherosclerosis as the consequence of the vascular response to the 
injurious effects of the classical cardiovascular risk factors []. It has become clear that as part 
of this vascular inflammatory response, in the early stages of atherosclerosis, affected vessels 
may undergo outward expansive remodeling to mitigate against incipient stenosis [2,3]. 
Epidemiological studies have established that smoking is a major risk factor for atherosclerotic 
ischemic heart disease [4-6]. The pleiotropic deleterious effects of smoking on atherosclerosis 
and thrombosis are beginning to be better delineated [7], however, the influence and impact of 
smoking on vascular remodeling remains poorly understood. Weissman and colleagues have 
reported that smoking is associated with focal contraction or negative remodeling of the 
atherosclerotic plaque [8]. Other groups however have reported that smoking does not influence 
remodeling mode or local plaque burden [9]. Evidence is emerging to suggest that as well as 
having a significant influence on the development of flow-limiting coronary stenoses, the 
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vascular remodeling mode may significantly impact on plaque stability, with plaques 
undergoing positive remodeling being more vulnerable to subsequent rupture and thrombosis 
[0-2]. The few studies examining the effect of smoking on plaque burden and the mode of 
vascular remodeling have been hampered by small numbers, and a lack of follow-up [8,9]. 
The last three decades has seen a growth in the use of percutaneous coronary 
interventions to manage symptomatic coronary atherosclerosis, however, despite the advent of 
drug-eluting stent technologies, the success of these techniques continues to be limited by 
restenosis [3]. The response to injury paradigm can also be employed to investigate this 
process and the vascular remodeling associated with it [4]. To date however, other major 
atherosclerotic risk factors have not emerged as risk factors for restenosis [5,6]. The influence 
of smoking on restenosis has been previously investigated with some studies suggesting a 
deleterious effect [7, 8] and other studies suggesting no direct effect [9-22]. These studies 
have been limited by small numbers [7], low follow-up rates [8,9], or a reliance on contrast 
angiography alone [2,22]. The latter invariably underestimates the extent of atherosclerosis, 
whereas intravascular ultrasound (IVUS) allows the vessel wall to be interrogated in exquisite 
detail and reveals the true burden of atheroma [23]. 
We investigated the effect of smoking on plaque burden, remodeling mode and on the 
process of restenosis in 039 patients undergoing percutaneous coronary intervention. Of these, 
450 patients underwent intravascular ultrasound study providing unique insights into the in vivo 
impact of smoking on the progression of atherosclerosis and restenosis.   
METHODS:
Study Design and End-points 
To determine the impact of smoking on coronary atherosclerosis and restenosis, we performed 
percutaneous coronary intervention in 039 patients at the Fujita Health University Hospital, 
Toyoake, Japan, Aichi Medical University Hospital, Nagakute, Japan, and Thoraxcenter, 
Erasmus Medical Center, Rotterdam, The Netherlands. Of these patients, 450 underwent 
intravascular ultrasound examination and the remainder contrast-angiography alone. The 
primary angiographic end-point was restenosis (defined as >50 percent diameter stenosis at 
follow-up by quantitative coronary angiography) and the primary clinical end-point was major 
adverse cardiac events (MACE: defined as sub-acute or late stent thrombosis, death, myocardial 
infarction, and target lesion revascularization) at six months follow-up. 
Patient Selection 
 The inclusion criteria were: () unstable or stable angina; (2) a single target lesion in a native 
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coronary artery with vessel diameter less than 4 mm; (3) either stenting or plain old balloon 
angioplasty (POBA); (4) agreement with angiographic follow-up. Patients were excluded from 
the study if they had: () contraindications to anticoagulation and antiplatelet therapy; (2) an 
acute myocardial infarction within the previous 7 days; (3) graft disease, left main coronary 
artery disease, or severe triple vessel disease; (4) an ostial lesion where the reference segment 
could not be identified in the IVUS group; (5) severe heavy calcification rendering it impossible 
to determine the true external elastic membrane (vessel) area in IVUS group; and (6) life 
expectancy less than a year.  The study was approved by local ethics committees and was 
carried out according to the guidelines of the Declaration of Helsinki. Written informed consent 
was obtained from all patients.  
Smoking history 
A history of smoking was requested as part of the routine work up. Patients were asked if they 
had never or ever smoked and whether they were continuing to smoke and their answers 
recorded on the data sheet. 
Percutaneous Coronary Intervention Procedures   
Percutaneous coronary intervention was performed according to standard clinical practice using 
the trans-radial or trans-femoral approaches. Guide catheters 6F or greater in size were used to 
facilitate subsequent quantitative coronary angiographic (QCA) analysis [24].  A bolus of 
8,000 to 0,000 IU of heparin (repeated if necessary) was administrated during the procedure, 
followed by a combination of antiplatelet therapy [24].  According to standard patient care, 
treatment with aspirin at a dose of 8 to 300mg daily was started before the procedure and 
continued indefinitely and treatment with ticlopidine at 200 mg daily was begun before or 
immediately after the procedure and continued for at least 2 weeks. 
Optimal Percutaneous Coronary Intervention Criteria 
Device sizes were determined by angiographic reference vessel diameter (angiography-guided 
group) and vessel size and plaque distribution detected by IVUS (IVUS-guided group). The 
angiographic criteria for optimal stenting were () no flow limiting dissection; and (2) residual 
stenosis less than 30%.  The IVUS criteria for optimal stenting were () good stent apposition; 
(2) full stent expansion with sufficient lumen area (lumen area 80% or greater of the average 
reference lumen area pre-intervention; and (3) the absence of major dissection [25,26]. 
Quantitative Coronary Angiography (QCA)  
Coronary angiograms were obtained in multiple views after the intracoronary injection of nitrates. 
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QCA analyses were performed using the computer-based edge-detection Coronary Angiography 
Analysis System (CAAS II, Pie Medical, Maastricht, the Netherlands) at the Coronary Imaging 
Core Laboratory in Aichi Medical and Fujita Health University [25-27]. The absolute diameter 
of the stenosis (in mm) was determined using the guiding catheter as a scaling device [27-29].  
To standardize the method of analysis for pre-, post- and follow-up angiograms, the study 
frames selected for analysis were end-diastolic to minimize motion artefact, and arterial 
segments were measured between the same identifiable branch points after the administration of 
nitrates [24, 27, 29]. Acute gain and late loss were calculated as the improvement in minimal 
luminal diameter (MLD) achieved at intervention (MLD post-intervention minus MLD pre) and the 
changes at follow-up (MLD post-intervention minus MLD at follow-up) respectively. Loss index 
(late loss divided by acute gain) was also studied. 
Intravascular Ultrasound Image Acquisition Protocol 
Following selective coronary angiography after the intracoronary injection of nitrates, a 
mechanical intracoronary ultrasound imaging catheter (40-MHz, 2.6Fr or 2.5Fr, Boston Scientific 
Corporation, Freemont, California, USA) was introduced over a 0.04-inch guide wire before, 
immediately after coronary intervention and at follow-up [29].  After the imaging catheter was 
passed into and beyond the lesion, a motorized pullback was started to obtain an assessment of the 
target lesion. IVUS images were stored on Super-VHS videotape for off-line analysis [29,30]. 
Quantitative IVUS Assessment
Serial IVUS analysis pre-procedure, immediately post-procedure and at six-month follow-up was 
performed at an independent core laboratory in Aichi Medical and Fujita Health University. 
Cross-sectional luminal area was defined as the integrated area central to the intimal leading edge 
echo [29-3].  The total vessel cross sectional area was defined as the area inside the interface 
between the plaque-media complex and adventitia (area inside the external elastic membrane) 
[3,29-3].  Vessel area, lumen area and plaque area were measured with a commercially 
available planimetry software package (TapeMeasure, Index Systems, Mountain View, California, 
USA) [3].  The lesion segment was determined from pre-intervention images including the 
frame with the smallest lumen area, while the proximal and distal reference segments were 
defined as the location of the least amount of disease within 0 mm proximal or distal to the 
lesion but before the emergence of a major side branch.  Remodeling index was defined as the 
ratio of the vessel area at the target lesion divided by the average of proximal and distal 
reference segment vessel area. The corresponding frames at post-intervention and follow-up 
were determined by using peri- and intra-coronary landmarks such as calcium deposits, side 
branches and venous structures [29-3]. With quantitative intravascular ultrasound, late lumen 
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loss was defined as lesion lumen area post-intervention minus lesion lumen area at follow-up; 
late intimal hyperplasia was defined as lesion plaque area at follow-up minus lesion plaque area 
post-procedure; and late vessel recoil was defined as the lesion vessel area post-procedure 
minus lesion vessel area at follow-up. 
Statistical Analysis 
Data was analyzed using the SAS statistical software package.  All continuous values are 
expressed as mean+SD.  Differences in categorical variables were assessed using the 
Chi-squared test and Fisher’s exact test.  The ANOVA test was used to assess differences in 
continuous variables between three groups.  Where multiple comparisons between sub-groups 
were necessary, Tukey’s method was used to assess the significance of differences observed by 
ANOVA.  To study the relationship between continuous outcome parameters and multiple 
categorical and continuous determinants, multiple linear regression analysis was used.  For all 
statistical tests, a two-tailed value of P<0.05 was considered significant. 
RESULTS:
Baseline Clinical and Angiographic Characteristics 
 A total of 039 patients entered the study. Of these 323 had never smoked, 468 were ex-smokers 
and 248 were still smoking at the time of the coronary intervention. Current smokers were 
significantly younger than non-smokers or ex-smokers (Table ).   
TABLE . Baseline Clinical and Demographic Characteristics. 
   Never  Ex-  Current  P 
Smoker   Smoker   Smoker  (ANOVA) 
(n=323)  (n=468)  (n=248) 
Age (years, meanrSD) 64.5r9.5 60.3r9.8 56.8r9.9 0.001
Male (%)  6.3  89.7  9.5 0.001
Diabetes Mellitus (%) 26.6  22.2  23.4  0.353 
Hypertension (%)  53.6  43.4  38.3  0.001
Hypercholesterolemia (%) 39.6  45.7  44.8  0.25
Previous MI (%)  22.9  3.8  27.8  0.023
Unstable Angina (%) 3.6  3.5  25.0  0.001
Coronary intervention was required on average 8 years earlier in smokers than non-smokers and 
nearly 4 years earlier in ex-smokers when compared with non-smokers (P=0.00).  There was 
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a significantly higher proportion of men in the current as well as ex-smokers groups (P=0.00).
While hypertension was more common in non-smokers (P=0.00), there was no significant 
difference in the other coronary risk factors including diabetes and hypercholesterolemia.  In 
spite of having a younger mean age, previous myocardial infraction was more common in 
current and ex-smokers (P=0.023) and current smokers were more likely to have unstable 
angina (P=0.00) relative to non-smokers. There were no significant differences in the baseline 
qualitative and quantitative angiographic characteristics between the three groups (Table 2).
TABLE 2. Angiographic Characteristics before and after Percutaneous Coronary Intervention. 
   Never  Ex-  Current  P 
Smoker   Smoker   Smoker   (ANOVA) 
(n=323)  (n=468)  (n=248) 
Target Coronary Artery (%) 
RCA   26.0  26.9  32.7  0.234 
LAD   55.  56.6  48.4  - 
LCX   8.8  6.4  8.9  -
AHA/ACC Lesion Class (%)  
A   24.8  26.9  27.8  0.958 
B   28.8  29.  29.0  - 
B2   38.7  35.5  34.7  - 
C   7.7  8.5  8.5  -
Overall (Stent & POBA) pre  
RD Pre (mm)  2.8r0.46 2.83r0.53 2.88r0.52 0.340 
MLD Pre (mm)  .00r0.3 .0r0.33 .02r0.37 0.75
MLD Post (mm) 2.9r0.44  2.23r0.44 2.27r0.47 0.2
MLD Follow-up (mm) .65r0.58  .74r0.56 .72r0.6 0.099 
Lesion Length (mm) .6r6. .2r5.8 .r5.6 0.583
Stent 
Acute Gain   .38r0.39 .43r0.45 .44r0.46 0.336 
  Late Loss  0.73r0.57 0.63r0.52 0.69r0.56 0.83 
Loss Index  0.53r0.47 0.45r0.4 0.52r0.5 0.52 
POBA
Acute Gain   0.95r0.39 0.97r0.39 0.99r0.45 0.667 
  Late Loss  0.3r0.46 0.35r0.48 0.38r0.49 0.567 
Loss Index  0.37r0.58 0.35r0.80 0.4r0.79 0.775 
Overall Restenosis rate (%)   
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24.3  24.6  25.4  0.955
RR with Stent  24. 6.6  20.9  0.73 
  RR with POBA  24.6  33.8  3.3  0.200 
RCA=Right Coronary Artery, LAD=Left Anterior Descending coronary artery; LCX=Left 
Circumflex coronary artery; RD=Reference Vessel Diameter; MLD=Minimal Lumen Diameter; 
POBA=Plain Old Balloon Angioplasty.
Comparison of Angiographic Restenosis Rates between Three Groups 
Follow-up angiography was performed in 963 (92.7%) of the 039 study patients and follow-up 
intravascular examination in 422 (93.7%) of the 450 who underwent pre-intervention 
intravascular ultrasound. There were no significant differences between the three groups with 
respect to follow-up rates (P=0.45). Similarly, no significant difference was found between 
non-smokers, ex-smokers, and current smokers with respect to the overall angiographic acute 
gain, late loss and loss index. Furthermore, no significant difference was observed between the 
three groups when the data were analyzed according to whether patients underwent stenting or 
POBA (Table 2).  The restenosis rates experienced by the three groups at 6 months follow-up 
were also similar. Once again, the lack of a significant difference was consistent regardless of 
whether patients underwent stenting or POBA. 
TABLE 3. Intracoronary Ultrasound Assessments in 450 patients. 
   Never  Ex-  Current  P 
Smoker   Smoker   Smoker   (ANOVA) 
(n=46)  (n=200)  (n=04)
Lesion morphology (stent and POBA) 
Soft/Fibrotic/Mixed/Calcified (%)  
6/2/30/7 5/3/32/4 55/2/3/2 0.343 
Calcium angle (degree) 76.r67. 7.r82.6 66.r86.5  0.609 
Reference (Ref) segment (stent and POBA) 
Proximal Ref VA pre (mm2) 4.5r4.3 5.4r4.5 6.6r4.8 0.002
Distal Ref VA pre (mm2) .9r4.6 2.r4.6 3.7r4.6 0.005
Average Ref VA pre (mm2) 3.2r4.0 3.7r4. 5.2r4.2 0.001
Average Ref PLA pre (mm2) 6.0r2.7  6.3r2.5  7.7r3.7  0.001
Lesion segment (stent and POBA) 
Lesion VA Pre (mm2) 2.4r4.0 3.0r4.3 5.5r4.7 0.001
Lesion PLA Pre (mm2) 0.6r3.8 .r4. 3.6r4.6 0.001
Remodeling Index  0.94r0.7 0.96r0.20 .04r0.23 0.001
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Stent
Late Loss  2.r2.3  2.4r2.2  2.5r2.5  0.664
Vessel Recoil  -0.5r3.4 -0.7r3.2 -0.7r3.8 0.903 
Plaque Growth  2.6r3.8  3.r3.6  3.4r4.2  0.475 
POBA
Late Loss  .0r2.2  .6r.9 .7r2.2  0.78
Vessel Recoil  0.3r2.5  0.2r5.2  0.6r4.2  0.88
Plaque Growth  0.6r3.0  .3r5.2  .r3.8  0.604 
IVUS=Intravascular Ultrasound; VA=Vessel Area; PLA=Plaque Area; POBA=Plain Old 
Balloon Angioplasty
Quantitative Intravascular Ultrasound Assessments and Restenosis 
Although qualitative IVUS lesion morphology was similar between the three groups, 
quantitative IVUS evaluation revealed marked differences (Table 3).  Reference vessel size 
either proximal or distal was significantly greater in smokers than non-smokers (proximal; 
P=0.002, distal; P= 0.005) and plaque burden in the reference segment was significantly greater 
in current smokers than non-smokers (P=0.00).  In the lesion segment, vessel area and plaque 
area were consistently greater in current smokers than non-smokers (vessel area, P=0.00;
plaque area, P=0.00).  Current smokers also had a significantly greater plaque burden than the 
other groups in both reference (P=0.00) and lesion segments (P=0.00).  Despite having a 
greater plaque burden in the reference segment, current smokers had a significantly greater 
positive remodeling index in the lesion segment relative to the other groups (P=0.00).
Although there was a significant difference in plaque burden among the three groups, no 
difference was observed in late loss, vessel recoil and plaque growth in both stent and POBA 
groups (Table 3), individually and overall.  
Clinical Outcomes at Six Months follow-up 
Eighty-nine (27.6%) of the non-smokers, 6 (24.8%) of the ex-smokers and 63 (25.4%) of the 
current smokers met clinical end-points (MACE; P=0.673).  Reflecting a similar restenosis 
rate, target lesion revascularization rates were similar between three groups (P=0.852).  No 
significant difference was observed between the three groups with respect to the occurrence of 
any MACE (Table 4). 
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TABLE 4. Comparison of Major Adverse Cardiac Events and Target Lesion 
Revascularization rates between the three groups. 
   Never  Ex-  Current  P 
Smoker   Smoker   Smoker   
(n=323)  (n=468)  (n=248) 
Death (n, %)  3 (0.9)  2 (0.4)  3 (.2)  0.483 
  Cardiac death (n, %) 3 (0.9)   (0.2)  2 (0.8)       0.367 
  Non-cardiac death (n, %) 0 (0.0)   (0.2)   (0.4)        0.546 
Myocardial Infraction (n, %)2 (3.7)  2 (2.6)  8 (3.2)  0.646 
TLR           
PCI (n, %)  59 (8.3)  9 (9.4)  45 (8.)  0.879 
CABG (n, %)  5 (4.6)   (2.4)  7 (2.8)  0.82 
Overall TLR (n, %) 74 (22.9)  02 (2.8) 52 (2.0)  0.852 
Overall MACE (n, %) 89 (27.6)  6 (24.8) 63 (25.4)  0.673 
TLR: Target Lesion Revascularization; PCI: Percutaneous Coronary Intervention;  
CABG: Coronary Artery Bypass Graft Surgery; MACE: Major Adverse Cardiac Events. 
Multivariate Analysis Results 
Multiple linear regression analyses to evaluate the respective contributions of clinical, 
angiographic and IVUS variables to plaque burden in the lesion segment indicated that 
smoking habit, male gender and unstable anginal symptoms were significant 
independent predictors for greater plaque burden (Table 5). 
TABLE 5. Summary Findings of Multiple Linear Regression Analysis of the 
Contributions of Clinical, Angiographic and Intravascular Ultrasound variables to 
Coronary Plaque Burden  
Regression  Standard Error of   P 
                       Coefficient  Regression Coefficient  
Smoking Habit   .23  0.283   0.001
Male Gender  .855  0.536   0.006
Unstable Angina Pectoris 0.885  0.46   0.034
Hypertension   0.744  0.396   0.06
Hypercholesterolemia 0.585  0.389   0.33
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DISCUSSION:
Our data indicate that there are marked differences in baseline clinical and IVUS characteristics 
between smokers and non-smokers, which cannot be detected by conventional contrast 
angiography alone. Smokers required coronary interventions on average eight years earlier than 
non-smokers and four years earlier than ex-smokers.  This is similar to the findings of Hasdai 
and colleagues who found that smokers required percutaneous coronary intervention on average 
ten years before non-smokers [32]. However, our data have also shown that once coronary 
intervention had been successfully done, six-month clinical and angiographic outcomes were 
similar between the three groups.   
The incidence of unstable angina was nearly double in current smokers in comparison to 
ex-smokers or non-smokers (current v ex- v non-smokers, 25.0% v 3.5% v 3.6%, P=0.00).
The greater plaque burden seen in the lesion and reference segments of current smokers and the 
positive remodeling mode observed could have played a role in fostering the development of 
unstable lesions (Table 3).  Our findings are in line with previous studies which have 
suggested that a positive or expansive remodeling mode is associated with plaque instability and 
an unstable clinical presentation [,2]. An alternative explanation for this finding is that 
smoking directly enhances plaque instability and results in an earlier clinical presentation with 
unstable disease whereas the older plaques seen in non-smokers have had more time to attain 
stability and undergo negative or constrictive remodeling. This could therefore perhaps result in 
a greater likelihood of presentation with stable disease in the older non-smokers. However, 
these scenarios are not mutually exclusive. Smoking results in endothelial dysfunction through 
decreasing nitric oxide production and enhancing oxidant injury [7, 33,34]. This provides a 
potent stimulus for the recruitment of macrophages to the plaque and their expression of matrix 
metalloproteinases, the gelatinase enzymes that are thought to play a key role in both vascular 
remodeling and the development of plaque instability [,35].   
Contrary to the findings of our study, a previous study by Weissman and colleagues found that 
smoking was associated with constrictive or negative remodeling [8]. However, only 6 of the 
69 patients entered into that study had adequate reference segments for study, and remodeling 
was only detected in 43 lesions, of which only 6 underwent negative remodeling. This 
provided only a limited sample size from which to draw definitive conclusions. 
Multivariate analysis demonstrated that smoking status is significantly related to plaque burden 
independent of age. Current smokers had significantly greater plaque burden not only in the 
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lesion segment but also reference segments, associated with positive vessel remodeling in the 
lesion segment. In spite of having a younger age, current smokers could therefore potentially 
have a greater longitudinal expansion of plaque deposits, that is, more diffuse disease.  This 
serves to highlight the deleterious effects of smoking on atherosclerosis. A previous IVUS study 
by Kornowski had suggested that smokers had similar arterial size and plaque burden in both 
reference and lesion segments [9]. However, in that study, smokers were not divided into current 
and ex-smokers, and smokers tended to have a greater plaque area and vessel size in comparison 
to non-smokers, albeit without a significant difference [9]. Their different classification of 
smoking status and sample size factors could have accounted for the differences between their 
findings and ours. 
Influence of Smoking on Restenosis 
Numerous studies have explored the impact of smoking on restenosis [7-22]. Two previous 
studies using QCA have suggested that restenosis rates were similar between smokers and 
non-smokers [2,22]. Our study represents the first large-scale use of IVUS with QCA to 
evaluate the impact of smoking status on restenosis. It was characterized by high follow-up rates 
(92.7%) and revealed that there was no significant difference in restenosis rates between 
smokers, ex-smokers and non-smokers. In particular, smoking had no effect on vessel recoil and 
plaque growth over the six months following PCI. These findings emphasize that although there 
are superficial similarities between the pathophysiological processes of atherosclerosis and 
restenosis, the vascular response to injury and remodeling which takes place in restenosis 
cannot be assumed to be subject to the same influences. This is exemplified by the finding in 
other studies that other classical risk factors such as hypercholesterolemia do not affect 
restenosis [5].  
Clinical Implications 
While those who continue to smoke after successful coronary intervention are at greater risk of 
Q-wave infarction and death than nonsmokers [32], the Framingham study reported that men 
under the age of 65 who were cigarette smokers at entry and subsequently stopped had 
myocardial ischemic attack rates which were half those experienced by those who continued to 
smoke [36].  In general, it has been observed that stopping smoking delays the onset of 
atherosclerotic disease by about a decade [6, 32].  Our smokers experienced PCI on average 
eight years earlier than nonsmokers, and four years earlier than ex-smokers.  IVUS indicated 
that ex-smokers had less plaque burden and negative remodeling as compared to current 
smokers.  Thus, smoking cessation, by removing a potent stimulus for endothelial injury and 
dysfunction, could favor changes in plaque structure that enhance plaque stability, thereby 
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reducing cardiovascular events during long-term follow-up. The finding that smoking status has 
no impact on restenosis should not therefore detract from the wealth of evidence from this and 
other studies reinforcing the importance of smoking cessation in retarding the development of 
atherosclerosis and reducing the risk of unstable disease [4-6,36]. 
Study Limitations 
Our study has a number of limitations.  Firstly, we do not have objective verification of the 
patient's self-reported smoking status, as we did not specifically assess whether supposed 
ex-smokers had truly stopped or whether they were still continuing to smoke.  Second, our data 
only apply to successful procedures and to the immediate 6-month follow-up period.  We 
therefore do not know if smoking reduces the chances of acute success or increases the 
immediate acute complications of the procedure. Furthermore, our study does not take into 
account any changes in smoking behavior that may have occurred following percutaneous 
coronary intervention. 
CONCLUSIONS 
 Smoking status did not significantly influence restenosis rates. However, current smokers 
required PCI nearly 8 years earlier than non-smokers and 4 years earlier than ex-smokers.  In 
spite of having a younger mean age, current smokers had a greater plaque burden in the lesion 
and reference segments, associated with a positive or expansive remodeling mode.  This was 
associated with an increased likelihood of unstable presentation. Thus, the time of percutaneous 
coronary intervention should be regarded as a golden opportunity to extol the health benefits of 
smoking cessation. 
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ABSTRACT:
Objectives: We investigated whether IVUS-guided Cutting Balloon Angioplasty (CBA) before 
stenting could achieve restenosis rates comparable to those achieved with drug-eluting stents 
(DES).
Background: Stent restenosis and thrombosis still occur even with DES and their long-term 
safety is uncertain. There remains a need to explore other strategies for ameliorating restenosis. 
Methods: We randomized 52 patients to CBA before stenting (260 pts) or plain old balloon 
angioplasty (POBA) before stenting. IVUS-guided procedures were performed in 279 (54%) 
patients and angiography guidance was used in the remainder. Patients were divided into 4 
groups based on device used before stenting and the use of IVUS-guidance (IVUS-guided CBA 
stent: 37; angiography-guided CBA stent: 23; IVUS-guided POBA stent: 42; and 
angiography-guided POBA stent: 9 patients). The primary end-point was restenosis. 
Results: The IVUS-guided CBA-stent strategy achieved a significantly lower restenosis rate of 
6.6% (p=0.06) versus rates of 7.9% (angiography-guided CBA-stent), 9.8% (IVUS-guided 
POBA-stent) and 8.2% (angiography-guided POBA-stent) in the remaining groups.  The 
device size used before stenting was significantly greater with IVUS than with 
angiography-guidance in CBA (3.37+0.4mm vs. 3.26+0.35mm, p=0.039) and with POBA 
(3.32+0.38mm vs. 3.9+0.4mm, p=0.00). Lumen area (LA) after CBA and POBA was 
significantly greater in IVUS-CBA than IVUS-POBA group (5.3+.6mm2 vs. 4.+.3mm2,
p=0.09) as was LA after stenting (7.4+2.2mm2 vs. 6.6+2.0mm2, p=0.035) and at follow-up 
(5.3+2.8 mm2 vs. 4.4+2.0 mm2, p=0.043). 
Conclusions: The IVUS-guided CBA-stent strategy provided restenosis rates (6.6%) similar to 
those achieved with DES. Such a strategy could therefore be a viable alternative to the use of 
DES.
INTRODUCTION:
Restenosis has been a major limitation to the success of percutaneous coronary 
intervention over the last two and a half decades. Whilst with the advent of drug-eluting stents, 
it would appear that the interventional cardiologist has overcome the nemesis of restenosis, 
there are significant concerns about the long-term efficacy and safety of such devices [,2]. 
Recent major multicenter randomized studies including RAVEL, SIRIUS and TAXUS have 
suggested that drug-eluting stents (DES) could drastically reduce 6-month restenosis rates to 
between 0-8.9% [3-5].  However, there is little long-term follow-up and safety data available 
beyond three years [,2,6].  A recent FDA public health report has warned that subacute 
thrombosis (SAT), late stent thrombosis (LST) and hypersensitivity reactions to sirolimus could 
have contributed to the serious major adverse cardiac events experienced in some patients 
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treated with DES [7].  Furthermore, a pathological study has suggested that a hypersensitivity 
reaction to the polymer of the DES could cause LST [8].  The number of DES and the stent 
length required for each lesion is substantially increasing based on the recent policy of full 
lesion coverage to avoid any potential injury at the stent edges. With the increasing cost 
constraints of modern healthcare practice, this could significantly limit the use of DES in 
clinical practice. Cost and long-term safety concerns highlight the need to continue to explore 
alternative strategies for reducing the burden of restenosis. 
The cutting balloon is a unique device that consists of a balloon catheter with three to 
four blades that creates longitudinal incisions in the atherosclerotic lesion during the balloon 
inflation.  While a randomized multicenter study of the use of cutting balloon angioplasty 
(CBA) without stent implantation or IVUS guidance failed to show a long-term advantage of 
CBA over plain old balloon angioplasty (POBA)[9], another study has indicated some clinical 
benefit [0].  We postulated that the use of IVUS guidance could be essential to obtaining 
optimal results with a strategy of cutting balloon angioplasty prior to stenting. IVUS can 
facilitate optimal device sizing based on vessel size and plaque distribution, and can reveal 
vascular wall injury after CBA. This may help to significantly reduce the incidence of vascular 
complications such as coronary perforation.  We hypothesized that IVUS-guided CBA prior to 
stenting would assist in achieving full stent expansion, improve accommodation of reactive 
intimal hyperplasia, and thereby produce favourable long-term restenosis rates comparable to 
those achieved with DES. 
To test this hypothesis we performed a prospective, randomized, multicenter trial to 
compare CBA with POBA before stenting in 52 patients with and without IVUS guidance. 
METHODS:
Study Design and End-Points 
The REDUCE trial was designed as a prospective, multicenter, randomized study to
compare cutting balloon angioplasty before the bare metal stent implantation and balloon 
angioplasty prior to stenting.  Five hundred twenty-one patients were randomly assigned to 
either cutting balloon prior to stenting or balloon angioplasty in an envelope manner at 37 
participating centers. To ensure an equal distribution of both treatments per center, the 
randomization sequence was developed on a site basis.  To compare IVUS-guided PCI and 
angiography-guided PCI, IVUS-guided procedures (pre and post) and follow-up were 
performed in 20 centers and angiography-guided procedures were done in the remaining 7.
While IVUS-guided procedures were performed in 279 (54%) patients, angiography-guided 
procedures were done in the remaining 242 (46%) patients.   
The primary angiographic end-point was restenosis (defined as >50 percent diameter 
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stenosis at follow-up by QCA) and the primary clinical end-point was major adverse cardiac 
events (subacute or late stent thrombosis, death, MI, and target lesion revascularization [TLR]). 
Patient selection 
 Patients with unstable angina, stable angina or silent myocardial ischemia, a single 
target lesion in a native coronary artery with a vessel diameter less than 4 mm, and planned stent 
implantation with up to 2 stents were included. Patients were excluded from the study if they 
had () contraindication to anticoagulation and antiplatelet therapy; (2) an acute myocardial 
infarction within the past 7 days; (3) graft disease; or (4) left main coronary artery disease. The 
study was approved by local ethics committees and was carried out according to the guidelines 
of the Declaration of Helsinki. Written informed consent was obtained from all patients. 
PCI procedures   
 CBA and POBA prior to the stent implantation were performed according to standard 
clinical practice using the trans-radial or trans-femoral approaches using guide catheters 6F or 
greater in size for subsequent quantitative coronary angiographic (QCA) analysis [].  A 
bolus of 8,000 to 0,000 IU of heparin (repeated if necessary) was administrated during the 
procedure, followed by a combination of anti-platelet therapy [].  According to standard 
patient care, treatment with aspirin at a dose of 8 to 300mg daily was started before the 
procedure and continued indefinitely and treatment with ticlopidine at 200 mg daily was begun 
before or immediately after the procedure and continued for at least 2 weeks. 
Optimal stenting criteria 
CBA, POBA and stent sizes were determined by angiographic reference vessel 
diameter (angiography-guided group) and vessel size and plaque distribution detected by IVUS 
(IVUS-guided group). The angiographic criteria for optimal stenting were () no flow limiting 
dissection; and (2) residual stenosis less than 30% [].  The IVUS criteria for optimal stenting 
were () good stent apposition; (2) full stent expansion with sufficient lumen area (lumen area 
80% or greater of the average reference lumen area pre-intervention; and (3) the absence of 
major dissection [2,3]. 
Quantitative Coronary Angiography (QCA)  
 Coronary angiograms were obtained in multiple views after the intracoronary injection 
of nitrates. QCA analyses were performed using the computer-based edge-detection coronary 
angiography analysis system (CAAS II, Pie Medical, Maastricht, NL) at the Coronary Imaging 
Core Laboratory at Aichi Medical University [2-4]. The absolute diameter of the stenosis 
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(in mm) was determined using the guiding catheter as a scaling device [4-6].  To standardize 
the method of analysis pre-, post- and follow-up angiograms, study frames selected for analysis 
were end-diastolic to minimize motion artefact, and arterial segments were measured between 
the same identifiable branch points after the administration of nitrates [,4,6]. 
Image Acquisition of Intracoronary Ultrasound (IVUS) 
Following selective coronary angiography after the intracoronary injection of nitrate, a 
mechanical intracoronary ultrasound imaging catheter (40-MHz, 2.7Fr or 2.5Fr, Boston Scientific 
Corporation, Freemont, California) was introduced over a 0.04-inch guidewire before, 
immediately after CBA or POBA, after stenting, and at follow-up [6,7].  After the imaging 
catheter was passed into and beyond the lesion, a motorized pullback was started to obtain an 
assessment of the target lesion. IVUS images were stored on super VHS videotape for off-line 
analysis [6,7]. 
Quantitative IVUS assessment (QCU)
Serial IVUS analysis pre-procedure, immediately after CBA or POBA, post-stenting and 
at 6-month follow-up were performed at an independent core laboratory at Aichi Medical 
University. Cross-sectional luminal area was defined as the integrated area central to the intimal 
leading edge echo [6-8].  The total vessel cross sectional area (VA) was defined as the area 
inside the interface between the plaque-media complex and adventitia (area inside the external 
elastic membrane) [6-8].  Vessel area (VA), lumen area (LA) and plaque area (PLA) were 
calculated by the imaging computer (Tapemeasure, Index Systems, Mountain View, California) 
[0,8].  The lesion segment was determined from pre-intervention images including the frame 
with the smallest LA, while the proximal and distal reference segments were defined as the 
location of the least amount of disease before the emergence of any major side branches. The 
corresponding frames at post-intervention and follow-up were determined by using peri- and 
intra-coronary landmarks such as calcium deposits, side branches and venous structures [6-8]. 
Statistical analysis 
 Data was analyzed using the SAS statistical software package.  All continuous values 
are expressed as mean+SD.  Differences in categorical variables were assessed using the 
chi-squared test and Fisher’s exact test.  The unpaired t test was used to assess difference in 
continuous variables between two groups and ANOVA for three or more groups.  To study the 
relationship between binary restenosis and multiple categorical and continuous determinants, 
multiple logistic regression analysis was performed.  Univariate variables with a p value <0.2 
were entered into the multivariate models.  Forward stepping was used to determine the 
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independent predictors of restenosis.  For all statistical tests, a two-tailed value of p<0.05 was 
considered significant.  All data were analyzed on an intention-to-treat basis. 
RESULTS:
Patient and Lesion Characteristics
Five hundred twenty-one patients entered the study, of which 260 were randomized to 
CBA before stent implantation and 26 to POBA prior to stenting. One hundred and thirty-seven 
patients underwent CBA and stenting under IVUS-guidance and 23 under 
angiography-guidance. One hundred and fourty-two patients underwent POBA under 
IVUS-guidance and the remaining 9 under angiography-guidance. All four groups were well 
matched without significant differences in baseline clinical, demographic and angiographic 
characteristics (Table ).
Procedure-related events 
Of the 260 patients randomized to CBA with stenting, four did not undergo CBA due 
to failure to cross the lesion but were successfully treated with balloon angioplasty and one did 
not undergo stent implantation after cutting balloon angioplasty. Two patients had myocardial 
infarction due to side branch occlusions.  Therefore the primary procedure success rate of CBA 
with stenting was 97% (253 out of 260 patients).  
Of the 26 patients randomized to POBA with stenting, all patients underwent 
successful POBA and stenting (procedural success, 00%).  One patient experienced sub-acute 
stent thrombosis with myocardial infarction 4 days after the procedure but received emergency 
PCI and TIMI III flow was quickly restored.  
Significant differences were observed in the nominal balloon size used prior to 
stenting among the four groups (Table 2).  The nominal device size used before stenting was 
significantly greater with IVUS-guidance than angiography-guidance in both the CBA group 
(3.37+0.4mm vs. 3.26+0.35mm, p=0.039) and the POBA group (3.32+0.38mm vs. 
3.9+0.4mm, p=0.00). The use of IVUS-guidance consistently resulted in the selection of 
greater device sizes prior to stenting than angiography-guidance alone.  
There was also a significant difference in the inflated balloon size measured by QCA between 
the four groups (Table 2).  The inflated balloon size was significantly greater in CBA than 
POBA groups (3.32+0.5mm vs. 3.20+0.42mm, p=0.035), although nominal balloon size was 
similar between IVUS-guided CBA and IVUS-guided POBA (3.37r0.4mm vs. 3.32r
0.38mm, p=0.348).
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Table . Baseline clinical and lesion characteristics. 
______________________________________________________________________________________________
 Cutting Balloon with Stent (n=260)         ____ POBA with Stent (n=26) ___   p 
 IVUS-CBA Angio-CBA IVUS-POBA Angio-POBA    (ANOVA)* 
 (n=37)  (n=23)  (n=42)  (n=9)
Age (yrs) 65r9  64r9  66r9  64r0  0.40
Male (%) 73.7  82.  79.6  73.  0.239 
DM (%) 27.0  27.6  36.6  28.6  0.264 
HT (%) 55.5  56.  57.0  6.3  0.787 
HLP (%)  43.8  48.8  37.3  50.4  0.34
Smokers  38.7  44.7  46.5  42.0  0.585 
MI (%) 32.  3.7  35.2  24.4  0.292 
Angina pectoris (%)          
UAP 26.3  24.4  27.5  27.7  0.930 
SAP 73.7  75.6  72.5  72.3  - 
Target artery (%)          
RCA 38.7  39.0  39.4  3.  0.770 
LAD 43.8  4.5  39.4  46.2  - 
LCX 7.5  9.5  2.  22.7  - 
AHA/ ACC lesion class (%)         
A 8.8  2.2  0.6  8.4  0.834 
B 32.  22.8  26.8  23.5  - 
B2 46.7  52.0  5.4  55.5  - 
C 2.4  3.0  .3 2.6  -
______________________________________________________________________________________________
QCA results  
While no significant difference was found in the baseline reference vessel size and 
minimal lumen diameter pre-procedure (MLD pre) between the four groups (Table 2), a 
significant difference was observed in the MLD post-procedure (p=0.034). The greatest 
MLD-post was achieved with IVUS-guided CBA with stenting and the smallest with 
angiography-guided POBA prior to stenting (Table 2).   
The overall angiographic follow-up rate was 87% (453 of 52 patients), with a mean follow up 
period of 6.8 months.  There was no significant difference between the four groups with regard 
to follow-up rates and duration. The incidence of restenosis was 6.6% (8 out of 22 patients) in 
the IVUS-guided CBA with stent group, 7.9% (9 out of 06 patients) in the 
angiography-guided CBA with stent groups, 9.8% (25 out of 26 patients) in IVUS-guided 
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POBA with stent group, and 8.2% (8 out of 99 patients) in angiography-guided POBA with 
stent group (p =0.06) (Table 2). 
Table 2. Comparison of procedural characteristics, QCA and IVUS.  
______________________________________________________________________________________________
 Cutting Balloon with Stent (n=260)       POBA with Stent (n=26)     p 
 IVUS-CBA Angio-CBA IVUS-POBA Angio-POBA    (ANOVA)* 
 (n=37)  (n=23)  (n=42)  (n=9)
Procedure characteristics  
Nominal balloon size (mm)  
3.37r0.4  3.26r0.35  3.32r0.38  3.9r0.4  0.003 
Inflated balloon size measured by QCA (mm)   
3.32r0.5  3.9r0.46  3.20r0.42  3.09r0.43  0.002 
QCA (mm)** 
RD pre  2.82r0.48  2.82r0.46  2.83r0.49  2.78r0.45  0.286 
MLDpre .05r0.32  .04r0.3 .03r0.28  .00r0.34  0.364 
MLDpost2.62r0.42 2.58r0.38  2.59r0.44  2.48r0.36  0.034 
MLDfup.88r0.54  .83r0.56 .8r0.58  .75r0.50  0.390 
Restenosis rate (%)** 
6.6  7.9  9.8  8.2  0.06
IVUS (mm2)
  LA pre  .7r0.8    .7r0.6    0.262 
LA post CB/POBA    
5.3r.6    4.r.3    0.09
LA post Stent    
7.4r2.2    6.6r2.0    0.035 
LA at follow-up  
5.3r2.8    4.4r2.0    0.043
______________________________________________________________________________________________
*ANOVA was applied only in four-group comparison and unpaired t-test was used in two IVUS group comparisons. 
IVUS results
While baseline lumen areas (LA) were similar between IVUS-guided CBA-stent and 
the IVUS-guided POBA-stent group, LA immediately after CBA was significantly greater than 
LA following POBA (5.3r.6mm2 versus 4.r.3mm2, p=0.09) (Table 2).  This favorable 
greater LA achieved by IVUS-guided CBA than by IVUS-guided POBA carried over after 
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stenting (7.4r2.2mm2 versus 6.0r2.0mm2, p = 0.035) and subsequently at follow-up (5.3r
2.8mm2 versus 4.4r2.0mm2, p=0.043).   
Table 3. Comparison of major adverse cardiac events (MACE) and target lesion 
revascularization (TLR) rates between four groups 
______________________________________________________________________________________________
    Cutting Balloon with Stent (n=260)         POBA with Stent (n=26)  p 
 IVUS-CBA Angio-CBA IVUS-POBA Angio-POBA    (ANOVA)* 
 (n=37)  (n=23)  (n=42)  (n=9)
Subacute stent thrombosis (SAT, n)   
0  0  0  *   0.336 
Late stent thrombosis (LST, n)  
0  0  0  0  - 
Death (n)   0  2  0  0.364 
MI (n)    0  *  0.766 
TLR (n, %)          
PCI 0 (7.3)   7 (3.8)  23 (6.2)  6* (3.4)  0.45
CABG  0  0  0   (0.8)  0.336 
Overall TLR (n, %)  
0 (7.3)  7 (3.8)  23 (6.2)  7 (4.3)  0.38
Overall MACE (n, %)  
2 (8.7)  8 (4.6)  25 (7.6)  9 (6.0)  0.7
______________________________________________________________________________________________
All MACE recorded even if one event led to another, *the same patient
Clinical Outcomes
One patient in the IVUS-guided CBA with stent group was lost to angiographic 
follow-up and died of a ventricular arrhythmia 2 months after the procedure (Table 3).  Late 
thrombosis or acute myocardial infraction was not observed in the CBA groups during 
follow-up period after the successful procedure, while two patients (one was IVUS-guided 
group the other was angiography-guided group) had procedure related myocardial infarction. 
In the POBA with stent group, one patient died of heart failure 4 months after the 
procedure and one patient without follow-up angiography died of lung cancer 2 months after 
the procedure. In the angiography-guided POBA with stent group, one patient had myocardial 
infarction due to subacute stent thrombosis (Table 3).   
There was a trend towards lower target lesion revascularization rates in the 
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IVUS-guided CBA group but this did not reach statistical significance (Table 3). Similarly, 
while the overall MACE was not significantly different between four groups, again the 
incidence of MACE was lowest in the IVUS-guided CBA group. 
Multivariate analyses results 
Multivariate analyses to evaluate the respective contributions of clinical, angiographic 
and IVUS variables to restenosis indicated that use of POBA but not CBA, smaller vessel area 
by IVUS, DM, LAD lesion location and stent length were independent predictors for stent 
restenosis at follow-up (Table 4).  Minimal lumen area post stenting tended to be a significant 
(p=0.072) but not an independent predictor. 
Table 4. Multiple logistic regression analysis to evaluate the respective contributions of clinical, 
angiographic and intracoronary ultrasound (IVUS) variables to restenosis (>50% diameter 
stenosis at follow-up) 
______________________________________________________________________________________________
Regression  Standard  p Odds Confidence 
Coefficient  Error  Ratio Limits 
 Lower Upper 
______________________________________________________________________________________________
POBA use   .69  0.489 0.00 5.425 2.078  4.60
Vessel size by IVUS  -0.24  0.067 0.002 0.807 0.707 0.922 
Diabetes   .423  0.454 0.002 4.49 .703 0.09
LAD location  .356  0.479 0.005 3.883 .58 9.933 
Stent length  0.054  0.026 0.04 .056 .002 .2
Min-CSA* post by IVUS 0.228  0.27 0.072 .256 0.979 .6
______________________________________________________________________________________________
*CSA: Cross-sectional area 
DISCUSSION:
 This prospective multicenter randomized study has demonstrated that the use of an 
IVUS-guided cutting balloon strategy prior to stent implantation can achieve acceptably low 
restenosis rates (6.6%) that are comparable to those achieved with drug eluting stents. There 
was a 97% procedural success rate with no sub-acute or late stent thrombosis despite the fact 
that 30% of patients were diabetics and the lesions tackled were typically long, in small vessels 
and complex in character (63% AHA/ACC lesion type B2/C). While IVUS guidance 
consistently provided greater nominal balloon size than angiography guidance alone, 
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IVUS-guided CBA consistently achieved a greater lumen area than IVUS-guided POBA 
immediately after balloon pre-dilatation, after stenting and subsequently at follow-up.  The 
greater lumen obtained by an IVUS-guided CBA strategy could have contributed to the 
favorable long-term outcomes observed.  Multivariate analyses indicated that use of POBA but 
not CBA, small vessels, DM, LAD lesion location and stent length were independent predictors 
for restenosis at follow-up. 
Mechanism of favorable outcome in IVUS guided CB prior to stent 
IVUS guidance allowed us to use significantly greater balloon sizes than those by 
angiography guidance in the CBA and POBA groups (Table 2).  Information about true vessel 
size and plaque distribution provided by IVUS significantly influenced the selected device size 
prior to the stent implantation and thereby significantly affected angiographic and clinical 
outcomes. 
Although nominal balloon size was similar between IVUS-guided CB and 
IVUS-guided POBA, the inflated CBA size by QCA was significantly greater than inflated 
POBA size (3.32r0.5mm vs. 3.20r0.42mm, p=0.035).  The greater inflated balloon size by 
CBA relative to POBA as well as the presence of cutting blades to create longitudinal incisions 
in the plaque may have contributed to the greater lumen area immediately after CBA relative to 
POBA (5.3r.6mm2 versus 4.r.3mm2, p=0.09).  This favorable effect of CBA also 
contributed to the greater lumen achieved after stenting (7.4r2.2mm2 versus 6.0r2.0mm2, p = 
0.035) and subsequently, the greater lumen area seen at follow-up (5.3r2.8mm2 versus 4.4r
2.0mm2, p=0.043) (Table 2).  These findings could explain the significantly lower restenosis 
rate (6.6%) in the IVUS-guided CBA group when compared with the other strategies (Table 2). 
Previous studies investigating the benefit of IVUS guided PCI strategy have yielded 
conflicting evidence.  While Fitzgerald and his coworkers indicated that IVUS guided stenting 
resulted in more effective stent expansion and subsequently, a lower restenosis rate in 
comparison with angiographic guidance alone [8], Mudra and his colleagues reported that 
optimizing stent implantation by IVUS failed to show beneficial effects on long-term outcome 
[9]. Mudra and his co-workers suggested that extensive experience with IVUS could produce 
similar final results to those without IVUS guidance.  However, our data indicated that selected 
nominal CB and POBA sizes were significantly greater in IVUS-guided group than 
angiography-guided group.  Recently, Oemrawsingh and Mintz and coworkers revealed that 
angiographic and clinical outcome after stenting for long lesions guided by IVUS is superior to
that by angiography alone [20].  This suggests that IVUS guidance could still confer an 
advantage in long or complex lesions as well as in the cutting balloon related procedures.   
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Comparison with Previous Cutting Balloon Studies 
While previous non-randomized studies indicated clinical benefit of this device[0], a 
multicenter study without IVUS and stenting failed to show an advantage of CBA over simple 
balloon angioplasty [9].  Our study is the first multicenter randomized trial comparing the 
strategy of using a CBA versus POBA prior to the stent implantation with and without IVUS 
guidance.  Since using cutting balloon blades to create longitudinal incisions within the plaque 
incurs the potential risk of extravasation or coronary perforation, an understanding of plaque 
distribution and true vessel size gained by using IVUS is vital to maximizing the effect of the 
cutting balloon while minimizing the risk of major complications.  We actually determined 
cutting balloon size including balloon length and the position based on the IVUS findings.  
This process may have some similarity to IVUS guided aggressive directional coronary 
atherectomy (DCA) rather than simple POBA or direct stenting [2].  Without IVUS guidance, 
an interventional operator tends to select undersized devices due to fears about the inherent 
danger of vessel perforation. This may negate the benefits of CBA and result in a sub-optimal 
smaller lumen similar to that which might be achieved with POBA. 
Impact of the CBA-stent Strategy in the Era of Drug Eluting Stent (DES)
While pre-clinical studies revealed modest suppression of intimal hyperplasia, the First 
experience In Man (FIM) and the RAVEL studies indicated complete inhibition of restenosis 
[3,22].  The broader application of DES in the SIRIUS study markedly reduced but did not 
eliminate the problem of restenosis.  Substantial growth in the real-life clinical use of DES has 
revealed some potential significant limitations.  A recent FDA public health notification has 
warned that the occurrence of subacute stent thrombosis (SAT), late stent thrombosis (LST) and 
hypersensitivity reactions to sirolimus may have significantly contributed to the serious adverse 
cardiac events experienced in some patients [7].  Both subacute and late stent thrombosis have 
been associated with non-fatal myocardial infarction or death [8,23-25]. Similar problems have 
bedeviled the use of intracoronary brachytherapy [26]. Furthermore, long-term safety beyond 
three to four years is not yet available, while conventional stent use has a history spanning 
nearly two decades.  In our study sub-acute and late stent thrombosis were not observed in the 
CBA arm and overall event-free survival of CBA with stent was 88.5% at follow-up.  
The SIRIUS study obtained restenosis rates of 8.9% and a more recent multicenter 
paclitaxel eluting stent showed restenosis rate of 7.9% [4,5].  While reference vessel size was 
similar in the SIRIUS study, TAXUS IV study and our own REDUCE study (SIRIUS: 2.80r
0.47mm, TAXUS IV: 2.75r0.47mm, our REDUCE: 2.80r0.47mm) and 64% of our patients 
had type B2/C, the restenosis rates of SIRIUS (8.9%) and TAXUS VI (7.9%) were similar to 
those achieved by our IVUS-guided CBA with bare metal stent strategy (6.6%) [4,5].  While it 
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is commonly believed that IVUS procedures are time consuming, it generally takes a few 
minutes in a single pullback in experienced IVUS catheterization laboratory.  Whilst the list 
price of a cutting balloon is $950, IVUS $640 and the bare metal stent price has rapidly fallen 
down in the recent market, the drug-eluting Cypher stent is $3,95 and the Taxus stent $2,950.  
Furthermore, a recent strategy for DES requires full coverage of the lesion (i.e. increasing stent 
length and number of stents used), and substantially pushes up the interventional cost.  Taking 
these circumstances into consideration, an IVUS-guided CBA-stent strategy could be an equally 
efficacious, safe, and cost-effective alternative to drug-eluting stents. 
Study Limitations 
 Firstly, patients with lesions suitable for less than two stents were included in this 
study therefore it is not known whether the results can be extrapolated to longer lesions 
spanning three or more stents.  Secondly, our data indicated that IVUS guided CBA prior to 
stenting contributed to reduced restenosis at follow-up. However, it is not confirmed whether 
IVUS guided direct stenting can obtain a similar outcome to the present study. 
Conclusions
Despite tackling complex lesion morphology in small vessel, this prospective 
multicenter randomized study clearly indicated that the use of CBA prior to a bare metal stent 
strategy had high procedural success rate (97%) with favorable event-free survival (88.5%) at 
follow-up. IVUS guided CBA and stenting conveyed low restenosis rates (6.6%) comparable to 
those achieved in recent DES studies, suggesting that this strategy could be a viable substitute 
for DES in some clinical settings. 
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Summary and Conclusion
Percutaneous coronary intervention (PCI) is a well established and effective therapy for patients 
with coronary artery disease.  Several diagnostic tools are available to guide therapeutic 
interventions, assess coronary lesion morphology and monitor chronological changes in 
coronary luminal dimensions including quantitative coronary angiography (QCA), intracoronary 
ultrasound (IVUS) and angioscopy.  Part I of this thesis (chapter 2 to 4) we assessed the 
reliability of these three quantitative and qualitative methodologies at the Thoraxcenter, 
Erasmus University, Rotterdam.  Using our validated primary methodological techniques, in 
part 2 of this thesis (chapter 5 to 8) we investigated the impact of abnormal vasomotor tone and 
smoking status on the progression and regression of coronary atherosclerosis.  In part 3 of this 
thesis (chapter 9 to 3) we evaluated the short- and long-term outcome of coronary stent 
implantation as well as cutting balloon angioplasty. 
Chapter 1 provides the introduction and overview of the thesis including the clinical, scientific 
and methodological background. 
Chapter 2 describes the measurements provided by geometric and videodensitometric QCA in 
comparison to IVUS measurements in 50 patients undergoing PCI. Following PCI the 
correlation between measurements of minimal lumen area by IVUS and those by edge-detection 
QCA was 0.74 in smooth contour, 0.46 in lesions with haziness, and 0.26 in lesions with 
dissection. Post PCI the difference between ICUS and videodensitometric QCA was less than the 
difference between ICUS and edge-detection QCA (P<0.0). We found that the complex 
morphological changes induced by intervention may contribute to the discordance between IVUS 
and QCA measurements. QCA with videodensitometry may be a complementary technique to 
edge-detection in lesions with complex morphology following PCI. 
Chapter 3 reports experimental and clinical QCA comparison between cinefilm and digital 
video recording with and without edge enhancement. The experimental angiographic studies 
were performed using plexiglass blocks and stenosis phantoms 0.5 to 3.0 mm diameter. The 
clinical angiograms were recorded in 20 patients undergoing PCI. In the experimental phantom 
study, the utilization of cinefilm resulted in the most precise QCA measurements. In the clinical 
series, the differences between measurements from cinefilm and digital video without 
edge-enhancement were 0.4+0.20 mm and from cinefilm and digital video with 
edge-enhancement were 0.04+0.3 mm.  These findings suggest that cinefilm is a more 
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reliable recording medium for QCA in scientific studies. However, for routine practice, digital 
video recording with edge-enhanced images may provide an acceptable alternative. 
Chapter 4 compares three imaging modalities including coronary angioscopy, intracoronary 
ultrasound (IVUS) and quantitative coronary angiography (QCA) in unstable and stable patients. 
Post-mortem studies suggest that plaque rupture with superimposed thrombosis is the primary 
mechanism responsible for acute coronary syndromes such as unstable angina, and that in 
particular, lipid-rich coronary plaques with thin fibrous caps are most prone to rupture.  We 
found that angioscopy demonstrated that plaque rupture and thrombosis were present in 7% of 
stable angina and 68% of unstable angina patients, although angiography discriminates poorly 
between lesions in stable and unstable angina. The ultrasound-derived plaque composition does 
not discriminate stable from unstable angina. While angioscopy is more sensitive in the 
presence of thrombus than the other modalities, intracoronary ultrasound could not clearly 
disclose differences in the characterization of atherosclerotic plaques in patients with stable or 
unstable angina. 
Chapter 5 evaluates the long-term changes in coronary luminal dimension in patients with 
persistent vasospastic angina in comparison with patients transient vasospastic angina 
symptoms, using QCA and repeated ergonovine provocation tests.  While it has been known 
for decades that coronary spasm frequently occurs at sites of significant atherosclerosis, it has 
not yet been determined whether vasospasm may play a role in the progression or regression of 
atherosclerosis.  The minimal luminal diameter (MLD) and mean diameter of 9 spastic 
segments was significantly smaller (progression) at follow-up compared to the initial angiogram 
(mean follow-up; 45r6 months). The MLD and mean diameter of 93 non-spastic segments 
were not different between initial and follow-up angiograms. In patients whose symptoms 
resolved, the MLD and mean diameter of the 7 previously spastic segments significantly 
improved (regression) at follow-up, whilst the MLD and mean diameter of the 8 non-spastic 
segments were not significantly different at follow-up. Our results have demonstrated in patients 
an association between persistent vasospastic activity and progression of atherosclerosis and an 
association between cessation of vasospastic activity and regression of atherosclerosis. 
Chapter 6 shows the relationship of long-term vasospastic activity to clinical presentations. 
Coronary spasm plays a role in a wide spectrum of ischemic coronary events including variant 
angina, and some cases of unstable angina and acute myocardial infarction.  Quantitative 
coronary angiography and repeated ergonovine tests revealed that some patients with persistent 
vasospastic angina demonstrate fluctuation of vasospastic location (22 of 48 spastic vessels), 
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while others exhibit a fixed location of vasospasm. Vasospastic angina may not only be a 
transient disease restricted in location but may also be a persistent and variable condition 
involving multiple vessels over many years. 
Chapter 7 addresses the role of coronary tone in the chronological changes of vasospastic 
anginal attacks.  We compared basal coronary tone and vasospastic activity during both initial 
and follow-up angiographic studies in 90 coronary segments of 3 patients. We measured 
changes in the mean luminal diameter (Mean LD) of each entire spastic segment, segments 
adjacent to the spastic segment, and segments in nonspastic vessels at baseline after 
administration of ergonovine and after administration of isosorbide dinitrate, using QCA.  The 
diagnostic sensitivity and specificity at 20% elevation of basal coronary tone for the prediction 
of vasospasm were 77% and 73%, respectively.  We found that contrary to some previous 
reports, the estimation of basal coronary tone may be useful in the assessment of vasospastic 
activity in patients with variant angina. 
Chapter 8 demonstrates the relationship between smoking status and plaque burden, vascular 
remodeling and restenosis in 039 patients undergoing PCI. IVUS examination was performed 
in 450 patients to determine vessel area, lumen area, plaque area and remodeling index. Of the 
039 patients, 248 were current smokers, 468 ex-smokers and 323 non-smokers. Current 
smokers were more likely to be younger than ex-smokers or non-smokers (P=0.00), and to 
suffer from unstable angina (P=0.00). Current smokers had a significantly greater plaque 
burden in the lesion (P=0.00) and were more likely to have a positive remodeling index 
(P=0.00). Restenosis rates were similar between the three groups (P=0.955). Although 
restenosis was not affected by smoking, current smoking appears to result in an earlier and 
unstable presentation of coronary disease, reinforcing the importance of smoking cessation. 
Chapter 9 represents the impact of Wallstent implantation on bailout management. We 
hypothesized that implantation of the oversized new Wallstents in native coronary arteries 
applying a policy of restitutio ad integrum (resetting the vessel size into the undiseased 
condition) would produce enforced mechanical remodelling of the coronary vessel with 
subsequent reduction in sub-acute occlusion and improved accommodation of reactive intimal 
hyperplasia. To test this hypothesis, we implanted 44 Wallstents in 35 native coronary arteries in 
35 patients with acute or threatened closure following balloon angioplasty. We found that the 
Wallstent implantation conveyed a favourable six month angiographic outcome with restenosis 
rates of 6%. The enforced mechanical remodelling induced by the new oversized Wallstent 
may result in prevention of acute and chronic recoil of the vessel wall and subsequently confer a 
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lower restenosis rate in patients requiring bailout management. 
Chapter 10 indicates the strategy of oversize Wallstent deployment for chronic total occlusion 
(CTO) in comparison with balloon angioplasty. We hypothesized that enforced mechanical 
remodelling by oversized stent implantation for CTO would convey a more favourable outcome 
than balloon angioplasty. The results were compared with a population of total occlusions 
undergoing successful balloon angioplasty and quantitative angiographic follow-up at 6 months 
in the same angiographic core laboratory. We found that oversized Wallstent implantation 
conveys a favourable short and long-term clinical and angiographic outcome (restenosis rate: 
29%) in comparison with conventional balloon angioplasty (restenosis rate: 45%) for CTO. 
Chapter 11 presents our early experience with the AVE stent primarily in long and complex 
coronary dissections after balloon angioplasty.  To determine the feasibility and safety of 
deployment of this stent, we deployed 28 AVE micro stents in 23 native coronary artery lesions 
in 20 patients who developed acute or threatened closure after balloon angioplasty.  The results 
of this early experience indicated that the AVE stent was deployed with a high procedural 
success rate (96%) and a minimal learning curve. Implantation of the stent as bailout 
management can be achieved with a low incidence of adverse cardiac events and a high 
angiographic success rate. 
Chapter 12 reveals the problem of restenosis assessment within the radio-opaque tantalum 
Cordis stent. To determine the reliability of geometric (edge-detection) quantitative 
angiographic analysis (QCA) of restenosis within a tantalum stent, we compared QCA and 
intracoronary ultrasound (ICUS) in both an experimental restenosis model (plexiglass phantom 
vessels with concentric stenosis channels ranging from 0.75 to 3.0 mm in diameter) and in the 
clinical follow-up of 23 patients. We found that IVUS measurements are unaffected by the 
radiopaque stent. However, the mechanical problem of IVUS catheter wedging and the 
substantial cost of IVCUS catheters could limit the widespread application of IVUS for the 
assessment of intra-stent restenosis. 
Chapter 13 discloses the impact of IVUS-guided Cutting Balloon Angioplasty (CBA) prior to 
stenting on restenosis at follow-up. We randomized 52 patients to CBA before stenting (260 
pts) or plain old balloon angioplasty (POBA) before stenting. IVUS-guided procedures were 
performed in 279 (54%) patients and angiography guidance used in the remainder. The 
IVUS-guided CBA-stent strategy achieved a significantly lower restenosis rate of 6.6% 
(P=0.06) versus rates of 7.9% (angiography-guided CBA-stent), 9.8% (IVUS-guided 
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POBA-stent) and 8.2% (angiography-guided POBA-stent) in the remaining groups. The 
IVUS-guided CBA-stent strategy could therefore be a viable alternative to the use of drug 
eluting stents in achieving significant reductions in restenosis rates following percutaneous 
coronary intervention. 
Chapter 14 conveys the conclusions of this project. 
In conclusion, while QCA is still the gold standard for the estimation of coronary stenosis in 
terms of a quick overview of entire coronary tree during the procedures, it is increasingly 
important to evaluate the tomographic dimensions of the coronary lumen and morphological 
composition of vessel wall by IVUS.  Our studies indicate that both QCA and IVUS are 
feasible and reliable techniques for estimating serial changes in coronary luminal dimensions. 
The use of QCA and IVUS has provided unique insights into the progression and regression of 
coronary atherosclerosis, and in particular the roles of smoking and coronary vasospasm. These 
techniques are also valuable for both studying and preventing restenosis. They have help to 
reveal that conventional coronary stenting, by supporting the vessel wall, limits early and late 
vessel remodeling and decreases restenosis.  While short to medium term restenosis seems to 
have been overcome by the advent of drug eluting stent (DES), several limitations still remain 
to apply this technique to all the patients.  IVUS guided cutting balloon angioplasty with 
stenting conveyed low restenosis rates (6.6%) comparable to those achieved in recent DES 
studies, suggesting that this strategy could be a viable substitute for DES in some clinical 
settings.  The ultimate goal of interventional cardiology is to substitute coronary artery bypass 
grafting (i.e. a more invasive form of treatment) for less invasive percutaneous revascularization 
and control the progression of coronary atherosclerosis in long-term follow-up.  The use of 
QCA and IVUS in concert with novel interventional strategies and devices heralds a new era in 
interventional cardiology in which these laudable aspirations may be realized.
Chapter 15 
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Samenvatting
Progressie en regressie van coronaire atherosclerose zijn een belangrijke determinant voor het 
klinisch beloop van patiënten met ischaemisch hartlijden. Evolutie van het coronarialijden kan 
gemeten worden middels kwantitatieve coronair angiografie (QCA), intravasculaire echo 
(IVUS) en angioscopie. Hiermee kan afhankelijk van de gebruikte methode het lumen en/of de 
pathologie in de vaatwand zelf onderzocht worden. Deze technieken werden in het 
Thoraxcentrum onderzocht en vergeleken met elkaar (hoofdstuk 2-4), evenals het effect van een 
afwijkend gedrag van de vaatwand (vaattonus) en roken op de evolutie van het coronarialijden 
(hoofdstuk 5-8). In hoofdstuk 903 werden de korte en lange termijn effecten van stent 
implantatie en cutting ballon angioplastiek geëvalueerd. 
Hoofdstuk  betreft de inleiding en samenvatting van dit proefschrift. 
In hoofdstuk 2 werd de geometrische en videodensitometrische QCA gegevens vergeleken met 
morfologische gegevens van IVUS in 50 patiënten die een PCI ondergingen. De correlatie was 
afhankelijk van de gebruikte techniek (contour detectie vs IVUS of videodensitometrie vs 
IVUS) en van de morfologische veranderingen van de plaque na PCI. Een belangrijke 
discordantie na PCI werd gevonden tussen IVUS en contour detectie. Mogelijk biedt 
videodensitometrie hiervoor een oplossing. 
Hoofdstuk 3 beschrijft experimenteel en klinisch onderzoek waarin de resultaten van QCA 
worden vergeleken bij analoge (cinefilm) en digitale (met en zonder randversterking) beelden. 
Voor de experimentele studies werden plexiglas modellen gebruikt met daarin een vernauwing 
van 0.5 tot 3.0 mm. De klinische experimenten hebben betrekking op 20 patiënten  die een PCI 
ondergingen. QCA meting in analoge beelden leverden de meest precieze resultaten op in het 
experimenteel onderzoek. Klinisch was het verschil tussen cinefim en digitale beelden het 
kleinst bij randversterking. (0.04 +/- 0.3 mm). Cinefilm geniet derhalve de voorkeur, zeker in 
het kader van wetenschappelijk onderzoek. Voor dagelijks gebruik is digitaal beeld met 
randversterking een goed alternatief. 
In hoofdstuk 4 worden QCA, IVUS en angioscopie onderzocht en vergeleken in patiënten met 
stabiele en onstabiele angina pectoris. Angioscopie toonde aan dat plaque ruptuur en thrombus 
aanwezig was bij 7% van de patienten met stabiele angina pectoris en bij 68% bij patiënten 
met onstabiele angina pectoris. Contrast angiografie kan niet of slecht het onderscheid maken 
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tussen stabiele en onstabiele plaques. Dat is ook het geval voor IVUS.  
In hoofdstuk 5 worden de veranderingen van het coronair lumen op lange termijn vergeleken 
tussen patiënten met persisterende en tijdelijke vasospastische angina pectoris. Hiervoor werd 
gebruik gemaakt van coronair angiografie (QCA) in combinatie met ergonovine. Van coronair 
spasme is bekend dat dit fenemeen vooral voorkomt in de coronair boom waar atherosclerose 
aanwezig is. Het is niet bekend of vasospasme een betrokken is bij progressie of regressie van 
coronaire atherosclerose. Progressie werd vastgesteld op de plaats van vasospasme bij patiënten 
met persisterende vasospastische angina. Regressie werd vastgesteld bij patienten bij wie 
klachten verdwenen. Deze bevindingen suggereren een relatie tussen vasospastische angina 
pectoris enerzijds, en pro- en regressie anderzijds, afhankelijk van persisteren of verdwijnen van 
klachten.
In hoofdstuk 6 wordt het effect van vasospasme op symptomen en klinische manifestaties op 
lange termijn onderzocht. Vasospame komt voor bij verschillende ziektebeelden zoals variant 
angina, onstabiele angina pectoris en zelfs acuut myocard infarct. QCA en ergonovine tests 
tonen aan dat de locatie van vasospasme in de coronair boom kan wisselen (22 van de 48 
onderzochte bloedvaten). Bij andere patiënten bleef de plaats van vasospasme onveranderd. 
Zoals eerder beschreven, kan vasospame ook een tijdelijk fenomeen zijn. 
In hoofdstuk 7 wordt de rol van coronaire vaattonus onderzocht bij patiënten met angina 
pectoris op basis van vasospasme.  De verandering van minimale lumen diameter (MLD) van 
9 segmenten van 3 patiënten werd met QCA (voor en na ergonovine en isosorbide dinitraat) 
onderzocht. Het betroffen segmenten met vasospasme, nabijgelegen segmenten en segmenten 
die geen vasospasme vertoonden. De gevoeligheid en specificiteit van QCA, uitgaand van een 
20% verandering van basale tonus, bedroeg 77 en 73%, respectievelijk. In tegenstelling tot 
eerder onderzoek, vonden wij dat de basale vaattonus wel van nut is voor het vaststellen van 
vasospastische angina pectoris. 
In hoofdstuk 8 wordt de relatie tussen, enerzijds, roken en, anderzijds, hoeveelheid plaque, 
vaatwand remodelleren en restenose bij 039 patiënten die een PCI ondergingen, onderzocht. 
IVUS werd bij 450 patiënten uitgevoerd voor het bepalen van de dimensies van de coronair 
arterie en plaque, evenals voor het bepalen van de index van het remodelleren. Van deze groep, 
waren er 248 patiënten die nog steeds roken, 468 waren gestopt met roken en 323 hebben nooit 
gerookt. Patiënten die nog steeds roken waren jonger en leden meer aan onstabiele angina 
pectoris. Ze hadden een significant grotere hoeveelheid plaque in de onderzochte vernauwing, 
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maar ook meer een positieve remodelleringsindex. Het optreden van restenose was gelijk in de 
drie groepen. Dit onderzoek suggereert dat roken leidt tot het eerder optreden van klinische 
tekenen van coronaire atherosclerose met tekenen van onstabiliteit. 
In hoofdstuk 9 wordt de hypothese onderzocht dat implantatie van een Wallstent , waarvan de 
ontplooide diameter groter is dan deze van het ontvangende vaatbed teneinde de initiële grootte 
van de coronair arterie te herstellen, gepaard gaat met een versterkte remodellering, minder van 
effect van eventuele neoinitma hyperplasie op de bloedstroom en minder stentafsluiting. Dit 
werd onderzocht bij 35 patiënten bij wie 44 stents werden geïmplanteerd wegens dreigende of 
acute afsluiting van een kransslagader na ballon angioplastiek. Restenose kwam voor bij 6% 
van de patiënten 6 maanden na implantatie. Het is mogelijk dat implantatie van een te grote 
stent in relatie tot de vaatdiameter gepaard gaat met een lagere kans op terugveren van de 
vaatwand en restenose. 
In hoofdstuk 0 wordt dezelfde hypothese onderzocht als in hoofdstuk 9 maar in patiënten met 
een chronische totale afsluiting van de kransslagader en in vergelijking met ballon angioplastiek. 
Restenose 6 maanden na stent implantatie was 29% en was 45% na ballon angioplastiek. 
Onderwerp van onderzoek in hoofdstuk  is de evaluatie van de toepasbaarheid en veiligheid 
van implantatie van de AVE micro stent. Dit werd geëvalueerd in 20 patiënten bij wie 28 AVE 
stents in 23 kransslagaderen werden geïmplanteerd wegens dreigende of acute vaatafsluiting na 
ballon angioplastiek. Stent implantatie verliep zonder problemen in 96% van de patiënten Er 
was een lage incidentie van cardiale gebeurtenissen en een hoog percentage van angiografisch 
geslaagde ingrepen. 
In hoofdstuk 2 wordt het optreden van restenose na implantatie van een tantalum Cordis stent 
onderzocht. Tantalum laat weinig Röntgenstralen door en kan derhalve QCA analyse met 
contour detectie verstoren. Daarom werd naast QCA ook IVUS uitgevoerd en met elkaar 
vergeleken. Dit werd uitgevoerd in een experimenteel model (fantomen uit plexiglas met 
gekende diameters) en klinisch (stent implantatie bij 23 patiënten). Zoals verwacht werd de 
IVUS meting niet verstoord door de radio-opake stent. Echter, technische factoren zoals 
afsluiten van het bloedvat door de IVUS catheter en prijs van de IVUS catheter zijn een 
beperkende factor voor het algemeen gebruik van deze techniek voor het bepalen van in-stent 
restenose.
In hoofdstuk 3 wordt het optreden van restenose onderzocht na cutting ballon angioplastiek 
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onder geleide van IVUS. In totaal werden 52 patiënten gerandomiseerd naar cutting ballon of 
standaard ballon angioplastiek gevolgd door stent implantatie in beide gevallen. IVUS werd 
uitgevoerd bij 279 patiënten (54%). Bij de overige patiënten werd enkel contrast angiografie 
uitgevoerd. Restenose na IVUS geleide cutting ballon angioplastiek was 6.6%, 7.9% na 
angiografische geleide cutting ballon angioplastiek, 9,8% na IVUS geleide standaard ballon 
angioplastiek en 8.2% na angiografische geleide standaard ballon angioplastiek. 
Besluit:
QCA is nog steeds de gouden standaard voor het bepalen van de ernst van een coronaire stenose. 
Tomografische dimensie van het lumen en inzicht in plaque compositie middels IVUS zijn in 
toenemende mate belangrijk voor het bepalen van het beleid van coronaire interventie. Zowel 
met QCA als IVUS kan op adequate wijze seriële veranderingen van het lumen van een 
kransslagader onderzocht worden.  
Prognose van een patiënt met coronaire atherosclerose is mede afhankelijk van pro- en regressie 
van het ziekteproces. Wij vonden dat coronaire spasme en cardiovasculaire risicofactoren zoals 
roken hierin een belangrijke rol spelen.  
Stent implantatie voorkomt vroeg en laattijdig remodelleren van de vaatwand en vermindert 
restenose. Het gebruik van stents die een medicijn afgeven aan de vaatwand (DES) verlagen zo 
mogelijk nog verder de kans op restenose. Gebruik van deze stents wordt gekenmerkt door een 
aantal beperkingen. Wij vonden dat restenose het laagst was na IVUS geleide cutting ballon 
angioplastiek met stent implantatie (6.6%). Dit komt overeen met de kans op restenose na DES 
implantatie. IVUS geleide ballon angioplastiek met stent implantatie kan derhalve overwogen 
worden als alternatief voor DES.
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